Evaluation of the effectiveness of the drug Samelix in patients with cholestasis in chronic alcoholic liver disease
https://doi.org/10.21518/2079-701X-2019-14-52-57
Abstract
A study of the clinical efficacy and safety of the drug Samelix (ademetionine, manufacturer – JSC «Canonfarma production», Russia) in 30 patients with chronic alcoholic liver disease (steatohepatitis mild to moderate currents, cirrhosis of the liver grade a ChildPugh) with the syndrome of cholestasis. Purpose of the study: evaluate the clinical efficacy and safety of Samelix (ademetionine) in 30 patients with chronic alcoholic liver disease. Objectives of the study: evaluate the effect of the drug on biochemical parameters, evaluate the effect of the drug on the clinical manifestation of the disease based on the individual diary data during the course therapy, assess the quality of life through the SF-36 questionnaire before and after treatment; report adverse events. The results of the study showed that therapy with this drug leads to a significant positive dynamics of biochemical parameters, regression of clinical manifestations of the disease, a significant increase in the quality of life. Good and excellent results of therapy were observed in 76.7% of cases. The drug is safe and well tolerated.
About the Authors
O. N. Minushkin
Central State Medical Academy;
Central Clinical Hospital No. 51 of Moscow Healthcare Department
Russian Federation
Russian Federation
Oleg N. Minushkin, Dr. of Sci. (Med.), Professor, Head of Chair for Gastroenterology, Federal State Budget Institution of Continuing Professional Education, Central State Medical Academy under Presidential Administration of the Russian Federation; State Budget Healthcare Institution of Moscow «City Clinical Hospital No. 51 of Moscow Healthcare Department»
L. V. Maslovsky
Central State Medical Academy;
Central Clinical Hospital No. 51 of Moscow Healthcare Department
Russian Federation
Russian Federation
Leonid V. Maslovsky, Dr. of Sci. (Med.), Associate Professor of Chair for Gastroenterology, Federal State Budget Institution of Continuing Professional Education, Central State Medical Academy under Presidential Administration of the Russian Federation; State Budget Healthcare Institution of Moscow «City Clinical Hospital No. 51 of Moscow Healthcare Department
M. I. Bulanova
Central State Medical Academy;
Central Clinical Hospital No. 51 of Moscow Healthcare Department
Russian Federation
Russian Federation
Mariya I. Bulanova, Resident Medical Practitioner of Chair for Gastroenterology, Federal State Budget Institution of Continuing Professional Education, Central State Medical Academy under Presidential Administration of the Russian Federation; State Budget Healthcare Institution of Moscow «City Clinical Hospital No. 51 of Moscow Healthcare Department
O. F. Shaposhnikovа
Central Clinical Hospital No. 51 of Moscow Healthcare Department
Russian Federation
Russian Federation
Olga F. Shaposhnikovа, Physician of Department of Ultrasound Diagnostics
7/33, Alyabeva St., Moscow, 121309
References
1. Lazebnik L.B., Firsova L.D. Alcoholic liver disease; mental and behavioral disorders due to alcohol use. Ehksperimental’naya i klinicheskaya gastroehnterologiya = Experimental & clinical gastroenterology. 2009;(3):130-136. (In Russ.) Available at: https://elibrary.ru/item.asp?id=15216445.
2. Chalasani N., Younossi Z., Lavine J.E. Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. doi: 10.1002/hep.25762.
3. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. Journal of Hepatology. 2012;57(2):399–420. doi: 10.1016/j.jhep.2012.04.004.
4. O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic Liver Disease. ACG Practice guideliness. Am J Gastroenterol. 2010;105(1):14–32. doi: 10.1038/ajg.2009.593.
5. Rambaldi A., Gluud C. S-adenosyl-Lmethionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;(2):CD002235. doi: 10.1002/14651858.CD002235.pub2.
6. Kononova A.G. Alcoholic liver disease: practical guidelines for general practitioners (family doctors). Tver; 2007. 46 с. (In Russ.) Available at: https://gigabaza.ru/doc/153591.html.
Review
For citations:
Minushkin ON, Maslovsky LV, Bulanova MI, Shaposhnikovа OF. Evaluation of the effectiveness of the drug Samelix in patients with cholestasis in chronic alcoholic liver disease. Meditsinskiy sovet = Medical Council. 2019;(14):52-57. (In Russ.) https://doi.org/10.21518/2079-701X-2019-14-52-57
Views:
1206
Email this article 